Abstract:

Autoimmune encephalitis （AE） is associated with immune-mediated antigen-antibody reactions involving the central nervous system. With the advent of autoantibody-associated diseases， the therapy of AE has become a hot research frontier in neuroimmunology. The conventional treatments of AE include first-line therapy and second-line therapy. The first-line treatments of AE include steroids， intravenous immunoglobulin （IVIG）， plasma exchange （PLEX）， and second-line therapy includes rituximab. However， current conventional therapy is ineffective for a considerable number of patients with AE. According to the current clinical trial evidence and single reports， tocilizumab is effective for refractory AE patients. With the current rapid research progress， a breakthrough in the treatment of AE is critical. This article aims to review tocilizumab in the treatment of refractory AE.

Key words:autoimmune encephalitis,tocilizumab,Actemra,therapy

摘要：

自身免疫性脑炎（autoimmune encephalitis， AE）是一种非感染性的自身免疫反应介导的炎性脑病。随着自身抗体相关疾病的研究进展，AE的治疗逐渐成为神经免疫领域的研究热点。AE的常规治疗为免疫治疗，大多数患者经一线及二线免疫治疗后症状好转，但仍有部分患者经免疫治疗后效果欠佳。托珠单抗（tocilizumab， TCZ）作为一种白介素-6受体拮抗剂，在难治性AE中的应用逐渐增多，本文对TCZ应用于难治性AE的国内外研究现状进行综述。

关键词:自身免疫性脑炎,托珠单抗,雅美罗,治疗